Key Points
- BridgeBio Pharma CAO Maricel Apuli sold 2,000 shares at an average price of $80.06, generating $160,120. The sale was conducted under a pre-arranged Rule 10b5-1 plan, leaving her with 127,401 shares.
- BBIO shares opened at $79.96, with the company valued at approximately $15.63 billion. The stock’s 12-month trading range is $42.09 to $93.42.
- Analysts maintain a consensus “Moderate Buy” rating with an average price target of $95.21, while BridgeBio’s latest quarterly results showed revenue growth of 66.8% year over year but an adjusted loss that missed estimates.
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CAO Maricel Apuli sold 2,000 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $80.06, for a total value of $160,120.00. Following the completion of the transaction, the chief accounting officer owned 127,401 shares of the company's stock, valued at $10,199,724.06. This represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
BridgeBio Pharma Trading Down 0.2%
Shares of BBIO stock opened at $79.96 on Tuesday. The business's 50-day moving average price is $74.44 and its 200-day moving average price is $72.80. BridgeBio Pharma, Inc. has a 12 month low of $42.09 and a 12 month high of $93.42. The firm has a market capitalization of $15.63 billion, a price-to-earnings ratio of -21.38 and a beta of 0.96.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.51 million during the quarter, compared to the consensus estimate of $178.07 million. During the same quarter in the prior year, the business posted ($0.88) EPS. The company's revenue was up 66.8% on a year-over-year basis. On average, sell-side analysts predict that BridgeBio Pharma, Inc. will post -2.27 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on BBIO shares. Canaccord Genuity Group initiated coverage on shares of BridgeBio Pharma in a report on Wednesday, June 3rd. They set a "buy" rating and a $104.00 target price on the stock. Truist Financial raised their price target on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a "buy" rating in a research note on Wednesday, April 29th. Weiss Ratings reiterated a "sell (d)" rating on shares of BridgeBio Pharma in a report on Friday, May 15th. Citigroup boosted their price objective on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the stock a "neutral" rating in a research note on Thursday, July 16th. Finally, Raymond James Financial downgraded BridgeBio Pharma from an "outperform" rating to a "market perform" rating in a report on Tuesday, May 26th. Twenty research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $95.21.
Check Out Our Latest Research Report on BBIO
Institutional Trading of BridgeBio Pharma
Several institutional investors have recently added to or reduced their stakes in BBIO. First Bank & Trust grew its position in BridgeBio Pharma by 1.6% in the 2nd quarter. First Bank & Trust now owns 8,797 shares of the company's stock worth $655,000 after purchasing an additional 142 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of BridgeBio Pharma by 13.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,646 shares of the company's stock worth $123,000 after buying an additional 199 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in shares of BridgeBio Pharma by 4.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company's stock worth $396,000 after buying an additional 244 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company's stock worth $39,000 after buying an additional 245 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its stake in shares of BridgeBio Pharma by 0.5% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company's stock worth $3,970,000 after buying an additional 246 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
